Effects of bone-targeted agents on cancer progression and mortality.
about
Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancerBisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidenceLow-intensity continuous ultrasound triggers effective bisphosphonate anticancer activity in breast cancer.Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myelomaTumour-derived miRNAs and bone metastasisBone-targeted therapy in metastatic breast cancer - all well-established knowledge?BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant diseaseBone marrow endothelium-targeted therapeutics for metastatic breast cancerNovel therapeutic targets in myeloma bone disease.Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcomaIncreased malignancy of oral squamous cell carcinomas (oscc) is associated with macrophage polarization in regional lymph nodes - an immunohistochemical studyRepurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancerBisphosphonates inactivate human EGFRs to exert antitumor actions.Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancerA new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancerAdjuvant bisphosphonates in breast cancer treatmentComparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma.Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic PerspectivesDynamic interplay between bone and multiple myeloma: emerging roles of the osteoblastCorrelation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-studyDoes estrogen play a role in response to adjuvant bone-targeted therapies?The SK-N-AS human neuroblastoma cell line develops osteolytic bone metastases with increased angiogenesis and COX-2 expression.Dual-therapy with αvβ3-targeted Sn2 lipase-labile fumagillin-prodrug nanoparticles and zoledronic acid in the Vx2 rabbit tumor model.Reimbursement for bone loss prevention is different between women with breast cancer and men with prostate cancer: time for a revision.Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells.Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities.The Inhibitory Effects of Forsythia Koreana Extracts on the Metastatic Ability of Breast Cancer Cells and Bone Resorption by Osteoclasts.Complications of cemented long-stem hip arthroplasty in metastatic bone disease revisited.Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myelomaBone targeted treatments in cancer - The story so farStrategies for obtaining bone biopsy specimens from breast cancer patients - Past experience and future directions.Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways.Necrotizing fasciitis as a rare complication of osteonecrosis of the jaw in a patient with multiple myeloma treated with lenalidomide: case report and review of the literature.Oral bisphosphonates and colorectal cancer.Estrogen related receptor alpha in castration-resistant prostate cancer cells promotes tumor progression in boneTranslating metastasis-related biomarkers to the clinic--progress and pitfalls.Modulators of HIF1α and NFkB in Cancer Treatment: Is it a Rational Approach for Controlling Malignant Progression?Management of cancer treatment-induced bone loss.Luminal breast cancer: from biology to treatment.
P2860
Q26746212-353B3924-F2EC-40C7-9BF1-BE84374AA75DQ26795493-72A9C914-6A0A-48A1-A0B8-FD91403ADD67Q27306861-B6B64A5C-B46F-4BDF-937F-818C26524F08Q28081996-37DBA0CE-FB3F-427F-85A4-4F04E0515FF4Q28086895-13F21C97-DEBA-480C-8429-C18CD1046E28Q28087676-EC0F1CFC-BE6A-4A42-AEF6-AC0DB2F1D3ADQ33798713-92884E67-D866-496F-B615-FEF06D04C872Q33911781-50592201-FBDB-4244-BF99-040727424347Q33943576-578B3B08-F541-4C3E-9A2C-A951DE7BBB2DQ34025065-E1485D48-E7B0-4C6B-AB2F-E21DC4046FB8Q34365891-AB1CE526-3F97-4567-9FE9-8207AEA79B97Q34468743-4C2AB01A-0205-487D-B802-FFEDAF85E85CQ34752800-A53789E4-D79B-4B8C-83B1-223FCE3DE13FQ34752876-B17043EE-7C82-42AD-9357-78055F37B580Q34945422-96E517F1-E134-46B6-9804-5428A94BAFFAQ34999463-51FC8314-CD1B-452F-A438-67275E28C3D7Q35066934-BFCDFB7D-5DBF-4560-A41B-7873E586BCCCQ35441390-7BD628F5-E225-45A3-84D0-896FFE67C262Q35667318-253C5BB7-B4D9-4F65-BE34-BF44E2F2F1B8Q36086488-AE0008B8-F624-4746-BB05-C941F9D8A646Q36207673-7846BF49-446F-4128-9F26-86DE404FF579Q36491529-444BC4F7-1F7A-481A-8B62-A505591764C0Q36492336-E00E4ED1-7F18-41E8-99F4-21F8D1464B4BQ36505441-9FA21503-FC62-4545-AC5A-96E9E454DB4FQ36677418-6862DA21-11FE-496C-B3FA-B145984ECFA0Q36907149-FF5DBE6D-1F0A-4F23-B0A1-71E8A7290A6BQ37043903-D14BECE5-A8E2-423F-BA2C-7F9A25CBD878Q37066418-9C952C7C-A79D-40BF-AE4B-458EC8C2F4D8Q37170895-2E870803-3F7E-4BD1-95E9-7C14E07AEBAAQ37332098-7A02AB9D-9481-453F-8B03-28C64779C394Q37337487-9310F0E9-99F2-48B4-AEF0-591D7DD2B3C6Q37500001-CCE5C906-0860-4B34-BF2B-43353F804240Q37577433-E3A4DE02-0FE3-4179-98DB-C1C9D63123BAQ37687106-7D0CC47B-2EF4-425E-B750-F21C35999B8FQ37692229-E500E2AE-FD6A-4633-8899-B8FAB37CF8D8Q37718338-964FAEC8-369E-4144-A095-F80349EFD767Q38079125-76BFCCD0-406C-47B0-97DC-63D879DC387BQ38081415-8072736B-F4A6-42A7-B04E-2913C9652592Q38090917-B9F06C4B-ECD7-4A2A-91BC-37A1E14A47BAQ38123680-305F2F14-EDBA-49BD-98E1-0DACBA841DB5
P2860
Effects of bone-targeted agents on cancer progression and mortality.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Effects of bone-targeted agents on cancer progression and mortality.
@en
type
label
Effects of bone-targeted agents on cancer progression and mortality.
@en
prefLabel
Effects of bone-targeted agents on cancer progression and mortality.
@en
P2860
P50
P356
P1476
Effects of bone-targeted agents on cancer progression and mortality
@en
P2093
Robert Coleman
P2860
P304
P356
10.1093/JNCI/DJS263
P407
P577
2012-07-02T00:00:00Z